Stonepine Capital Management LLC Purchases New Shares in HilleVax, Inc. (NASDAQ:HLVX)

Stonepine Capital Management LLC purchased a new stake in HilleVax, Inc. (NASDAQ:HLVX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 132,347 shares of the company's stock, valued at approximately $274,000. Stonepine Capital Management LLC owned 0.27% of HilleVax as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Barclays PLC increased its stake in HilleVax by 14.1% during the fourth quarter. Barclays PLC now owns 47,946 shares of the company's stock worth $100,000 after acquiring an additional 5,913 shares during the last quarter. Northern Trust Corp boosted its stake in shares of HilleVax by 2.8% in the 4th quarter. Northern Trust Corp now owns 249,610 shares of the company's stock valued at $517,000 after buying an additional 6,916 shares during the period. SG Americas Securities LLC increased its position in shares of HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after purchasing an additional 6,916 shares during the last quarter. Ieq Capital LLC lifted its holdings in HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock worth $47,000 after buying an additional 9,344 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after purchasing an additional 11,459 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a research report on Monday, March 31st. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $3.00.

HilleVax Stock Down 0.8%

Shares of HLVX traded down $0.02 during mid-day trading on Friday, hitting $1.85. 26,371 shares of the company's stock were exchanged, compared to its average volume of 448,699. The stock has a market cap of $92.51 million, a price-to-earnings ratio of -0.60 and a beta of 0.78. HilleVax, Inc. has a twelve month low of $1.34 and a twelve month high of $15.60. The firm has a fifty day moving average of $1.73 and a two-hundred day moving average of $1.84.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.25. On average, equities analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.